Pharmaceuticals, Biotechnology and Life Sciences
– Presentation to be webcast on www.exelixis.com – ALAMEDA, Calif.–(BUSINESS WIRE)–Exelixis, Inc. (Nasdaq: EXEL) today announced that members of Exelixis…
– Conference Call and Webcast to Follow at 5:00 p.m. EDT / 2:00 p.m. PDT – ALAMEDA, Calif.–(BUSINESS WIRE)–Exelixis, Inc.…
Exelixiswill receive an associated $20 million milestone payment from DaiichiSankyo under the terms of the companies’ collaboration agreement.
Ipsen and Exelixis on Tuesday said that their phase 3 study of study of cabozantinib in patients with advanced liver…
Exelixis and Bristol-Myers Squibb have entered into a clinical development collaboration to evaluate Cabometyx (cabozantinib), Exelixis’ small molecule inhibitor of receptor tyrosine kinases, with Opdivo (nivolumab), Bristol-Myers Squibb’s PD-1 immune checkpoint inhibitor, either alone or in combination with Yervoy (ipilimumab).
Exelixis and Ipsen have signed an amendment to the exclusive collaboration and licensing agreement for the commercialization and continued development…
Ipsen and its partner Exelixis today announced detailed results from the CABOSUN randomized phase 2 trial of cabozantinib in patients with previously untreated advanced renal cell carcinoma (RCC) with intermediate- or poor-risk disease per the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).